Colorectal Cancer Pipeline Outlook 2025: Clinical Trials, Therapies, and Market Insights

Strategic Insights -

The report highlights the robust landscape of Colorectal Cancer (CRC) pipeline, with over 195 active players working to develop 200+ pipeline therapies. DelveInsight's 2025 report provides comprehensive insights into the CRC pipeline, including clinical trial studies, EMA, PDMA, FDA approvals, MOA, ROA, NDA, IND, and companies.

Key Takeaways:

  • On August 29, 2025, Merck Sharp & Dohme LLC announced a phase 3 study of Pembrolizumab (MK-3475) versus chemotherapy in Chinese participants with stage IV microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colorectal cancer (MK-3475-C66).
  • On August 28, 2025, Oncoinvent AS conducted a phase 1/2a open-label study to evaluate the dose, safety, tolerability, and efficacy of an IP alpha-emitting radionuclide therapy (Radspherin) in subjects with peritoneal carcinomatosis from colorectal carcinoma following complete cytoreduction score (CC-0).
  • DelveInsight's CRC pipeline report depicts a robust space with 195+ active players working to develop 200+ pipeline therapies.
  • The leading CRC companies, such as Exelixis, Mirati Therapeutics, Merck Sharp & Dohme LLC, Daiichi Sankyo Company, Inspirna, Lyell Immunopharma, Genentech, Cantargia AB, Arcus Biosciences, Inc., Neogap Therapeutics AB, Criterium, Inc., Daiichi Sankyo, Inc., Bristol-Myers Squibb, Celyad Oncology SA, Pfizer, Akeso, and others, are involved in targeted therapeutics development.

Statistics:

  • 195+ companies are working to develop 200+ pipeline therapies for CRC treatment.
  • The leading CRC companies have a presence in the market with a focus on targeted therapeutics development.
  • 80+ pipeline therapies are in late-stage development, with 50+ therapies in Phase III and 30+ therapies in Phase II.
  • 30+ pipeline therapies are in mid-stage development, with 20+ therapies in Phase I and 10+ therapies in discovery/preclinical stages.
  • The largest portion of pipeline therapies is in small molecule development (40%), followed by monoclonal antibody (30%), and recombinant fusion protein (15%).

Sources:

  • M2 PRESSWIRE: Colorectal Cancer Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies (C)1994-2025 M2 COMMUNICATIONS RDATE:01092025
  • DelveInsight's Colorectal Cancer Pipeline Insight 2025 report
  • DelveInsight's Colorectal Cancer Pipeline Report Provides Insights into the Therapeutic Assessment of the Pipeline Drugs by the Route of Administration